Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Phase II data show improvements in GM2 gangliosidosis with IB-1001

Aug. 20, 2021

Vyant Bio to collaborate with Cyclica on discovery of treatments for CDKL5 deficiency disorder

Aug. 20, 2021

Esteve Pharmaceuticals presents new analgesic drugs

Aug. 20, 2021

Vigil Neuroscience advances TREM2 agonists

Aug. 20, 2021

Bright Minds Biosciences compound reduces seizures in animal models of Dravet syndrome/epilepsy

Aug. 20, 2021

Brexpiprazole does not meet primary endpoint in borderline personality disorder trial

Aug. 19, 2021

Ganaxolone reduces seizure frequency in tuberous sclerosis complex patients

Aug. 18, 2021

Phase I study of Alzheimer's disease candidate AL-001 to begin in September

Aug. 18, 2021

DNMT3a and DNA methylation alterations in the nucleus accumbens are involved in PTSD-like behavior

Aug. 18, 2021

Green light for censavudine to initiate phase II trial in neurodegeneration

Aug. 17, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 19, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Authorities work to quickly sequence Ebola species in latest outbreak
BioWorld
If the recent hantavirus outbreak wasn’t enough to keep public health officials busy, a new Ebola virus disease outbreak has been confirmed by authorities in the...
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...